- RecruitingPhase I/II
A Phase I/IIa trial of NVG-222 in blood cancers
This trial tests a new drug, NVG-222, for blood cancers. It aims to find the safest dose, understand side effects, and see if it can shrink or control cancer by helping the body's immune system fight cancer cells. It's for adults whose cancer has returned or is not responding to other treatments.
For: Haematological malignanciesUnited Kingdom · England - Not yet recruitingPhase I/II
A Phase I/IIa trial of NVG-222 in participants with solid tumours
This study is testing a new drug, NVG-222, for advanced solid tumours. It aims to find a safe dose, understand side effects, and see if it can shrink cancer. NVG-222 helps your immune system target and kill cancer cells, and includes a safety 'off-switch'.
For: Solid tumoursUnited Kingdom · England